Human Longevity (HLI), a genomic-based health intelligence company, secured USD 39.8 million in a Series B funding round led by TVM Capital healthcare, with participation from Panacea Venture and Emerging Technology Partners. This brings the total funds raised by the company to USD 380.3 million.
The new funds will be used to invest in HLI's AI health risk and recommendation platform, new longevity-focused technologies and services, and new expansion sites globally.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.